Recently, several studies have been devoted to elucidating potential targeted therapies for GBM, and several such strategies were designed against key GBM oncogenic genes/pathways such as BRAF [40] and FGFR1/FGFR2/FGFR3 [40]. This evidence concerns the gene BRAF and glioblastoma.